Daliresp (Roflumilast): Targeted Anti-Inflammatory Therapy for COPD Exacerbation Reduction – A Comprehensive Clinical Review

I remember the first time I truly understood what Daliresp could do. It was about three years ago, Mrs. G, 68-year-old former smoker, GOLD stage 3 COPD, FEV1 hovering around 38% predicted. She’d been on triple therapy for years – tiotropium, salmeterol/fluticasone, the works. Still, she was in my office every six to eight weeks with another exacerbation. “Doctor, I can’t keep doing this,” she told me, still catching her breath from the walk from the parking lot.